Additionally, as CTLA-4 inhibitors have gained notoriety as a standard treatment option for NSCLC in combination with PD-L1 inhibitors, questions have been raised regarding the comparative efficacy of PD-L1/CTLA-4 versus PD-L1/platinum regimens. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.